| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PRKAR1A; CAR; CNC; CNC1; PKR1; PPNAD1; PRKAR1; TSE1;;PRKAR1A |
| WB Predicted band size | Calculated MW: 43 kDa ; Observed MW: 48 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human PRKAR1A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇涉及PRKAR1A抗体的参考文献摘要概括：
---
1. **文献名称**: "Mutations of the PRKAR1A gene in familial and sporadic cardiac myxomas"
**作者**: Kirschner LS, et al.
**摘要**: 该研究通过Western blot和免疫组化分析，使用PRKAR1A特异性抗体检测心脏粘液瘤患者组织中PRKAR1A蛋白表达缺失，发现PRKAR1A基因突变导致蛋白功能异常，与Carney复合征相关。
---
2. **文献名称**: "Immunohistochemical analysis of PRKAR1A in adrenal cortical neoplasms"
**作者**: Bertherat J, et al.
**摘要**: 利用PRKAR1A单克隆抗体对肾上腺皮质肿瘤组织进行染色，发现PRKAR1A表达水平与肿瘤恶性程度呈负相关，提示其作为肾上腺疾病生物标志物的潜力。
---
3. **文献名称**: "PRKAR1A regulates mitochondrial oxidative phosphorylation in cancer cells"
**作者**: Cao Y, et al.
**摘要**: 通过siRNA敲低PRKAR1A并结合抗体检测蛋白水平，揭示PRKAR1A通过调控线粒体氧化磷酸化通路影响肿瘤细胞能量代谢，为靶向治疗提供依据。
---
4. **文献名称**: "Antibody-based profiling of cAMP-dependent protein kinase signaling defects in Carney complex"
**作者**: Stratakis CA, et al.
**摘要**: 采用PRKAR1A多克隆抗体分析患者成纤维细胞，证实PRKAR1A缺失导致cAMP/PKA信号通路异常活化，阐明了Carney复合征的分子机制。
---
以上文献均通过抗体实验(如Western blot、免疫组化)探讨PRKAR1A在疾病中的作用，覆盖功能研究及临床应用方向。
The PRKAR1A antibody is a crucial tool in studying the regulatory subunit of protein kinase A (PKA), a central mediator of cAMP signaling. PRKAR1A (Protein Kinase cAMP-Dependent Regulatory Type I Alpha) is encoded by the PRKAR1A gene and serves as a key component of PKA holoenzyme, regulating its activity by binding catalytic subunits. Mutations in PRKAR1A are linked to Carney complex (CNC), a rare genetic disorder causing endocrine tumors, skin pigmentation, and cardiac myxomas. The antibody detects PRKAR1A protein expression, aiding in research on PKA signaling dysregulation, tumorigenesis, and CNC pathophysiology.
PRKAR1A antibodies are utilized in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein levels, localization, and post-translational modifications. They help identify PRKAR1A loss or truncation in CNC-associated tumors, where mutations often lead to unstable protein products degraded via nonsense-mediated decay. Commercial antibodies target specific epitopes, with validation in human and murine samples. Researchers also employ these antibodies to explore PRKAR1A's role in cell cycle regulation, cAMP-responsive pathways, and interactions with tumor suppressors like PDE11A.
Clinically, PRKAR1A antibodies assist in diagnosing CNC and differentiating it from other endocrine disorders. Their specificity and reliability make them vital for both mechanistic studies and translational applications in cAMP-related diseases.
×
